Legend Capital, an investment firm based in Beijing, led a $150m Series E round in ClinChoice, a global clinical CRO, with participation from Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures and Apricot Capital. "We thank the investors for their trust in ClinChoice. This round of capital investment fully validates ClinChoice's rapid growth and future potential in the field of clinical CRO. With the new round of financing, we will further enhance our innovative service offering and continue business expansion by organic growth and M&A, in order to better serve our clients worldwide," Ling Zhen, ClinChoice Global Chairman and CEO.